Brief: Editas Medicine And Genevant Sciences To Collaborate To Develop Novel Mrna-Lnp Gene Editing Therapeutics
21/10/2024 21:41
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering